Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the shares. The company reported Q4 earnings beat and the management’s FY25 outlook has “room for upside”, the analyst tells investors in a research note. Boston Scientific’s multiple growth drivers include the “unrelenting” Pulsed Field Ablation System story, a beat in Urology, and P&L leverage, Truist added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $115 from $100 at Stifel
- Boston Scientific price target raised to $120 from $112 at Baird
- Boston Scientific price target raised to $117 from $101 at Canaccord
- Boston Scientific price target raised to $122 from $107 at Citi
- Boston Scientific Reports Strong 2024 Financial Growth